Pcn102 the Burden of Renal Cell Cancer: A Retrospective Longitudinal Study on Occurrence, Outcomes and Cost Using an Administrative Claims Database

Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies

“…Despite the importance of mccRCC, studies evaluating its economic burden are sparse [18][19][20][21][22][23][24][25][26][27]. Most of them were conducted before 2011 and before targeted therapies appeared on the market [18][19][20][21][22].…”

“…Despite the importance of mccRCC, studies evaluating its economic burden are sparse [18][19][20][21][22][23][24][25][26][27]. Most of them were conducted before 2011 and before targeted therapies appeared on the market [18][19][20][21][22]. However, targeted therapies for mccRCC have brought both new hope and new challenges, considerably expanding the number of treatment options for this indication.…”

“…On the other hand, clinical and economic studies in daily practice are sparse [18][19][20][21][22][23][24][25][26][27]. A previous retrospective multicenter study was conducted to assess the effectiveness of targeted therapies in real life settings [28].…”